After the report on its adverse effects, AstraZeneca stops selling its Covid vaccine in the European

After the report on its adverse effects, AstraZeneca stops selling its Covid vaccine in the European
After the report on its adverse effects, AstraZeneca stops selling its Covid vaccine in the European Union

The laboratory AstraZeneca will stop selling your Covid vaccine in the European . The measure will come into effect this Tuesday, after the European Commission accepted a request from the pharmaceutical company to withdraw the product from the market that had been presented on March 5.

The resolution comes days after the pharmaceutical company admitted for the first time that its coronavirus vaccine could cause rare adverse effects, such as thrombosis.

Meanwhile, Justice is processing a class action lawsuit filed by those who claim to have suffered serious adverse effects after receiving this injection, which was developed in collaboration with the University of Oxford and which was one of the first to be applied in Argentina.

“We will now work with regulators and our partners to align ourselves on a clear path forward to conclude this chapter and our significant contribution to the Covid-19 pandemic,” they pointed out from the Spanish subsidiary of the laboratory, through an official statement published by the newspaper El País.

The vaccine recorded some cases of thrombosis which led to the limitation of the product during 2021. The trials accelerated the explanation times and last week it had become public that the pharmaceutical company admitted for the first time, in official documents, that its vaccine could cause rare adverse effects. Among them, thrombosis.

For now, the laboratory insists that, despite these extremely low risks of serious adverse effects, the concrete benefits of vaccination outweigh the side effects that are only possible.

The Astrazeneca laboratory will stop selling its Covid vaccine to the EU.

The vaccine in question – unlike, for example, that of Pfizer, with messenger RNA technology, or the Russian Sputnik, which was prepared with human adenoviruses – is based on a chimpanzee adenovirus as a platform.

Once in the body, the body generates the immune response to that antigen without causing disease. At the time, the double dose AstraZeneca proved to be between 85% and 90% effective against symptomatic Covid-19 disease.

According to some British media, the laboratory accepted in a legal document presented to the High Court of that country that its vaccine “can, in very rare cases, cause TTS.” This means that it can form blood clots and a low platelet count.

However, AstraZeneca does not directly link the withdrawal of its vaccine to the multiple legal proceedings that were opened in recent months as a result of side effects.

“As multiple updated vaccines have been developed for Covid-19 variants, there is now a surplus of vaccines available. This causes a decrease in demand for our vaccine, which is no longer manufactured or supplied,” the letter concludes.

AstraZeneca sold 22 million doses to Argentina

With AstraZeneca being one of the first vaccines for which a contract was signed for 22 million doses (although it arrived after Sputnik) and one of the most applied in the country, the news from the United Kingdom activated timeless fears in Argentina, focused on whether Such thrombosis, although rare, could occur long after receiving the injection.

To avoid these unjustified fears, Daniela Hozbor, principal investigator of CONICET at the VacSal Laboratory of the Institute of Biotechnology and Molecular Biology (IBBM), clarified that “in general, the reported cases (in Argentina) occurred between 4 and 10 days after vaccination. I didn’t see anything after that time, nothing that appeared in the long term, otherwise we would have already detected it.

These clots, he adds, which can appear in different parts of the body and even cause ailments, have treatment. But Hozbor asks to convert these fears about symptoms “that rarely occur” into confidence in the widespread effectiveness of vaccination.

“The benefit of the AstraZeneca vaccine is higher than the risk, and the only novelty is that the pharmaceutical company admits the appearance of serious adverse effects in very rare cases,” he concludes.

For Latest Updates Follow us on Google News


PREV Cuba congratulates the Dominican president on his re-election – Juventud Rebelde
NEXT Australia and New Zealand send evacuation flights to New Caledonia after week of deadly unrest